Teva Pharmaceuticals last week announced it has obtained the FDA approval for Ajovy (Fremanezumab) for migraine prevention. The news boosted its shares. Indeed, many analysts expect the drug to generate annual sales up to $1bn (2021).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,